
PTHS Stock Forecast & Price Target
PTHS Analyst Ratings
Bulls say
Pelthos Therapeutics Inc has demonstrated significant revenue potential with an impressive increase in net revenue projections for 4Q from $4.5 million to $16.2 million, driven by a 40% growth in October prescriptions compared to the previous month. The company has reported a strong momentum in prescription growth, with 2,189 units prescribed in October alone, marking a 41% sequential increase that exceeded the third quarter's total prescription volume. Furthermore, Pelthos is enhancing its market presence by expanding its sales force from 50 to 64 territory managers, targeting an increase in coverage to approximately 10,000 clinicians, which could lead to substantial revenue growth from its existing commercial model.
Bears say
Pelthos Therapeutics Inc faces significant challenges that present a negative outlook for its stock. Key risks include potential inadequacies in securing reimbursement and formulary placements, which may hinder market uptake and adversely impact sales and profit margins. Additionally, competitive pressures from other products and potential operational disruptions, such as supply chain issues or failures in clinical trials, could further impede revenue growth and overall financial stability.
This aggregate rating is based on analysts' research of Pelthos Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
PTHS Analyst Forecast & Price Prediction
Start investing in PTHS
Order type
Buy in
Order amount
Est. shares
0 shares